bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1712762
| Field | Detail |
|---|---|
| Company | Bioaffinity Technologies, INC. (BIAFW) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on March 5, 2024, updating investors on financials.
AI Summary
On March 5, 2024, bioAffinity Technologies, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is involved in commercial physical and biological research.
Why It Matters
This filing provides an update on bioAffinity Technologies' financial condition and operational activities, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not introduce new risks.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive office location
FAQ
What is the primary purpose of this 8-K filing for bioAffinity Technologies, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on March 5, 2024.
In which state is bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. is incorporated in Delaware.
What is the business address of bioAffinity Technologies, Inc.?
The business address is 22211 W Interstate 10 Suite 1206, San Antonio, Texas 78257.
What is the Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc.?
The SIC code is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-05 17:26:46
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 30KB
- 0001493152-24-008897.txt ( ) — 317KB
- biaf-20240305.xsd (EX-101.SCH) — 4KB
- biaf-20240305_def.xml (EX-101.DEF) — 26KB
- biaf-20240305_lab.xml (EX-101.LAB) — 36KB
- biaf-20240305_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 5, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer